Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis versus Ozurdex 6-month extension study in retinal vein occlusion-related macular edema
2011-005045-13Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab and ozurdex in Vein occlusion (RVO), branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) (2 arms), sponsored by Novartis. Primary endpoints: Long-term safety profile comparison, Ocular and non-ocular adverse events during extension and 1 more. Started Dec 2011; status: completed.
02
Drugs
ranibizumabozurdex
03
Conditions
Vein occlusion (RVO)branch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2011-005045-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005045-13.